Oncology Clinical Trials in Lebanon, NH
As of September 2026, 70 paid clinical trials are recruiting for Oncology in Lebanon, New Hampshire. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Lebanon
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
71 clinical trials for Oncology
·Clear filters·A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Project: Every Child for Younger Patients With Cancer
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Top Research Study Locations in Lebanon
Researchers run research studies in Lebanon, NH at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8, B Acute Lymphoblastic Leukemia | 66 |
| Dartmouth-Hitchcock Medical Center | Neoplasm Metastasis, Trauma Injury, Cancer | 65 |
| Dartmouth Hitchcock Medical Center | Amyotrophic Lateral Sclerosis, Epilepsy, Anesthesia | 56 |
| Dartmouth Hitchcock | ALK Genomic Tumor Aberrations, Advanced Cancer, Advanced Solid Tumor | 9 |
| Dartmouth Cancer Center | Adjuvant Treatment, Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab | 5 |
| Dartmouth Health | Colorectal Adenoma, Colorectal Cancer, Colorectal Neoplasms | 5 |
| Dartmouth-Hitchcock Clinic | Breast Cancer, Fragility Fracture, Infant | 4 |
| Ascendis Investigational Site | Growth Hormone Deficiency | 2 |
| Clinical Study Site | Metastatic Colorectal Cancer (CRC), Non-Small Cell Lung Cancer | 2 |
| Dartmouth College | Anorexia Nervosa, Binge Eating Disorder, Bulimia Nervosa | 2 |
| Dartmouth Hitchcock Medical Center | Carcinoma, Non-Small-Cell Lung | 2 |
| Dartmouth-Health | Spastic Hemiparesis, Spinal Fusion, Spinal Stenosis | 2 |
| Dartmouth-Health Lebanon | Cognitive Dysfunction, Memory Disorders, Memory Dysfunction | 2 |
| Dartmouth-Hitchcock | Cognitive Dysfunction, Cognitive Disorder, Epilepsy, Leukemia | 2 |
| Dartmouth-Hitchcock Clinics | Depression, Major Depressive Disorder, Obesity | 2 |
| Dartmouth-Hitchcock Medical Center-Norris Cotton Cancer Center | Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis | 2 |
| Alice Peck Day Memorial Hospital | Suicide Attempt, Suicide Ideation | 1 |
| Children's Hospital at Dartmouth: Geisel School of Medicine | Child, Critical Illness, Hospital Acquired Pressure Ulcer | 1 |
| Cinical Study Site | Chronic Inflammatory Demyelinating Polyneuropathy | 1 |
| Clinical Trial Site | Lichen Planopilaris | 1 |
| Darthmouth-Hitchcock Medical Center | Alzheimer Disease | 1 |
| Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center | Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer | 1 |
| Dartmouth Geisel School of Medicine | Spine Surgery | 1 |
| Dartmouth Hitchcock Cancer Center | Advanced Melanoma | 1 |
| Dartmouth Hitchcock Clinics Heater Road | Pyoderma Gangrenosum | 1 |
Active & Upcoming Studies in Lebanon (2026)
Recruiting trials in Lebanon grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (120 active studies)
- Understanding Information Preferences, Risk Perceptions, and Tradeoffs When Making Decisions About Multi-cancer Early Detection Tests · Trustees of Dartmouth College
- Implementation Intention Planning Guide for FIT Colon Cancer Screening · Dartmouth-Hitchcock Medical Center
Neurology & pain (16 active studies)
- Epileptiform Potential of Fully Immersive Virtual Reality · Dartmouth-Hitchcock Medical Center
- HOBSCOTCH-YOUTH and Young Adults · Dartmouth-Hitchcock Medical Center
Cardiovascular (8 active studies)
- Psychological Trauma, Post-Traumatic Stress Disorder, and Resilience in Adults With Congenital Heart Disease · Dartmouth-Hitchcock Medical Center
- Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention · Phase 4 · Duke University
Mental health & behavior (7 active studies)
- Digitally Enhanced Peer Doula Model for Perinatal Patients With Substance Use Disorder · Trustees of Dartmouth College
- Remote Evaluation and Alerting for Collaborative Health (REACH) in Depression · Dartmouth-Hitchcock Medical Center
Diabetes & metabolic (5 active studies)
- Phentermine's Impact on Treatment in Teens · Phase 2 · Russell McCulloh, MD
- Pilot Trial of the Move Healthier Group · Dartmouth-Hitchcock Medical Center
Pediatric (2 active studies)
- Participatory Approaches to Qualitative Research (PAQ): Comparing Two Approaches to Patient, Public and Clinician Involvement in Qualitative Research · Dartmouth-Hitchcock Medical Center
- Optimizing Tracheal Intubation Outcomes and Neonatal Safety · Children's Hospital of Philadelphia
Common conditions studied in Lebanon
- Acute Myeloid Leukemia (6 active studies)
- Breast Cancer (6 active studies)
- Epilepsy (6 active studies)
- Carcinoma, Non-Small-Cell Lung (5 active studies)
- Ulcerative Colitis (5 active studies)
- Non-Small Cell Lung Cancer (4 active studies)
Leading research sponsors in Lebanon
- Dartmouth-Hitchcock Medical Center
- National Cancer Institute (NCI)
- NRG Oncology
- Children's Oncology Group
- Alliance for Clinical Trials in Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Lebanon?
There are approximately 254 recruiting clinical trials in Lebanon, New Hampshire listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Lebanon pay participants?
Most recruiting trials in Lebanon compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Lebanon?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Lebanon?
The most common conditions under active study in Lebanon include Acute Myeloid Leukemia (6), Breast Cancer (6), Epilepsy (6), Carcinoma, Non-Small-Cell Lung (5), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Lebanon?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Lebanon on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Lebanon?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Lebanon?
Recruiting research sites in Lebanon include Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center, Dartmouth Hitchcock Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Lebanon right now?
The largest active categories in Lebanon are Cancer & tumors (120), Neurology & pain (16), Cardiovascular (8). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.